Area of research
Oncology · Cancer Research
Research interest
Research interests include Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, and Cancer Treatment and Pharmacology.
Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study.
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer
A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
ESMO Resilience Task Force recommendations to manage psychosocial risks, optimise well-being, and reduce burnout in oncology
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy
Pregnancy After Breast Cancer in Young <i>BRCA </i>Carriers
European Society of Cardiology Core Curriculum for Cardio-Oncology
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies
Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative Data
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer
Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics
Emerging Therapeutics for Patients with Triple-Negative Breast Cancer
OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline <i>BRCA1/2 </i>mutations and high-risk HER2-negative early breast cancer.
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)
Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations